FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
−0.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.78
From 52W high−74.25%
Volume3.66M
Market cap$286.88M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.78
From 52W high
−74.25%
Volume
3.66M
Market cap
$286.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
−0.27%
YTD Return
−66.58%
SummaryUpdated Jun 1, 2026
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in July 2019 and focuses on developing treatments for genetically defined rare diseases with high unmet medical need. Fulcrum has evolved from pursuing multiple therapeutic programs to concentrating primarily on <b>pociredir</b> for sickle cell disease, following the discontinuation of its lead program <b>losmapimod</b> for facioscapulohumeral muscular dystrophy (FSHD) in 2024 after Phase 3 trial results failed to meet endpoints.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC is investigating the proposed merger of Fulcrum Therapeutics, Inc. and Slate Medicines, Inc., under which Fulcrum shareholders are expected to own 5.0% of the combined company.32d agoFulcrum Therapeutics and Slate Medicines announced a merger agreement to combine and operate as Slate Medicines, focusing on advancing next-generation migraine therapies.34d agoGreg Tourangeau departed as Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc. by mutual agreement, effective 2026-08-07.42d ago